Longitudinal Compression of Drug Eluting Stents with resultant potential shrinkage will be reviewed at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco next week
Following CE Mark approval in 2009, Abbott now gains FDA approval for Xience Prime Drug Eluting Stent
bbott’s EXCEL is the Largest Trial to Date Designed to Evaluate Optimal Treatment Strategy (Surgery or Stenting) in Patients with Unprotected Left Main Disease
Carotid stent use “Quality of Life” benefits were reduced to equivalence compared with surgery at the one year time point in a 2500 patient randomized multicentre study.
Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent: results of the EXAMINATION trial
The board of directors of Abbott today declared a quarterly common dividend of 48 cents per share
Abbott has announced the initiation of ABSORB BTK, an international clinical trial evaluating the safety and efficacy of the ABSORB™ bioresorbable vascular scaffold (BVS) for the treatment of below-the-knee (BTK) critical limb ischemia.
Abbott has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD.
The results of the first randomised controlled trial comparing percutaneous mitral valve repair against conventional mitral valve surgery suggests the short term advantages of the technique may be outweighed by inferior long term results compared with conventional surgery.